The history of copyright's flagship drug presents a interesting case for stakeholders in the pharmaceutical sector. While initially a phenomenal success, generating billions, the intellectual property expiration and the subsequent entry of off-brand versions have significantly affected earnings. This raises questions about the ongoing profitability